Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.
Andrew Li, PharmD, BCOP
Advertisement
Articles by Andrew Li, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
2
What Heidi Overton's FDA Nomination Could Mean for Pharmacy
3
FDA Approves Bixlenvo Once-Daily Single-Tablet Regimen for Virologically Suppressed Adults With HIV
4
FDA Approves Tirzepatide to Cut CV Risk in Type 2 Diabetes
5